High-dose versus low-dose intravenous iron reduces myocardial infarctions in patients receiving maintenance hemodialysis<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Dec. 22, 2021 (HealthDay News) — For patients on maintenance hemodialysis, high-dose versus low-dose intravenous (IV) iron can help reduce the risk for myocardial infarction (MI), according to a study published online Dec. 7 in Cardiovascular Research<\/em>.<\/p>\n Marc C. Petrie, M.B.Ch.B., from the University of Glasgow in the United Kingdom, and colleagues conducted a prespecified analysis of secondary end points from a randomized clinical trial involving adults who had started hemodialysis within the previous year, had a ferritin concentration <400 \u00c2\u00b5g\/L, and had a transferrin saturation <30 percent. A total of 2,141 participants were randomly assigned to either high- or low-dose IV iron.<\/p>\n The researchers found that 8.4 percent of participants experienced an MI during a median follow-up of 2.1 years. The rate of type 1 MIs was higher than the rate of type 2 MIs (3.2 versus 1.3\/100 patient-years), and non-ST-elevation MIs were more common than ST-elevation MIs (3.3 versus 0.5\/100 patient-years). After nonfatal MI, mortality was high (one- and two-year mortality of 40 and 60 percent, respectively). Compared with reactive low-dose IV iron, proactive high-dose IV iron reduced the composite end point of nonfatal and fatal MI (hazard ratio, 0.69) and nonfatal MI (hazard ratio, 0.69) in time-to-first event analysis. High-dose IV iron had less of an effect on recurrent MI events than on the time-to-first event analysis.<\/p>\n “Very few therapies investigated in people on dialysis have been shown to improve outcomes,” Petrie said in a statement. “Our hope [is] that this treatment is used around the world in people with kidney failure on dialysis.”<\/p>\n Several authors disclosed financial ties to the biopharmaceutical industry; the study was partially funded by Vifor Fresenius Medical Care Renal Pharma.<\/p>\n